TSH Biopharm Corporation Limited (TPEX:8432)
48.25
-0.40 (-0.82%)
Jun 18, 2025, 1:30 PM CST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
Cardiovascular and Gastrointestinal Drugs | 565.24M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cardiovascular and Gastrointestinal Drugs Growth | 13.66% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Reinvestment | 550.48M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Reinvestment Growth | 75.53% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Lozenges | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Lozenges Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Testing | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Testing Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Capsules | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Capsules Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Service | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Service Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Injections | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Injections Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Sales Returns and Allowances | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Sales Returns and Allowances Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
Taiwan | 1.12B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Taiwan Growth | 37.59% |
Log In |
Log In |
Log In |
Log In | Upgrade
|